Scryb -- ehemals Vervielfachungschance_ChroMedX (Seite 1101)

[temptoo]

Hat jemand eine Übersetzung dafür?
Bin nicht so gut im Englisch.

[Jet-Stream]

Und wieder starke News mit starken Aussagen. Chart sieht übrigens auch super aus trotz BaFins Kursmanipulation.

[Pepecoin]

👍👍👍🍀

[Goldbarren999]

ChroMedX appoints Gil as CEO, Kent as president

2018-01-05 16:11 ET - News Release


Mr. Gerard Edwards reports

CHROMEDX CORP. EXPANDS EXECUTIVE TEAM; LAHAV GIL APPOINTED CEO AND DIRECTOR

ChroMedX Corp. has appointed medtech (medical technology) visionary Lahav Gil as chief executive officer and W. Clark Kent as president of the company. Both have also been appointed to the company's board of directors.

Mr. Gil joins ChroMedX as the founder and former chief executive officer of the innovative Toronto-based medical device industrial design and productization organization, Kangaroo Group (ISO 13485). Mr. Gil founded the company in 2003 and evolved it into a full-spectrum outsourcing platform for medical device innovation, engineering, design, productization, RA (remittance advice) submissions and contract manufacturing, contributing to many product launches in the Canadian and international medtech industry. Kangaroo was acquired by full-service medical device design company Starfish Medical in April, 2017.

"Lahav's achievements speak for themselves, but his energy, vision and passion for design and development is something truly remarkable," said Gerard Edwards, executive chairman of ChroMedX. "This appointment is an exciting milestone in a plan that the board of directors have been working on for quite some time. We are proud to appoint Lahav as chief executive officer and welcome him to the board of directors."

Mr. Gil is well known in the community for his strong team-building abilities and emphasis on innovation culture, as well as his record as a medtech entrepreneur, design-driven innovator and business leader.

"With the HemoPalm, ChroMedx is well positioned to bring a remarkable and critically needed product to market," said Lahav Gil, chief executive officer and a director of ChroMedX. "Successful commercializing of a medical device relies on a deep and profound understanding of the problems that you are trying to solve at all levels of the product and business offering. Critically understanding the requirements of all the stakeholders, including those leading to a strategic acquisition, are key to this success, as well as designing for frictionless adoption models, a superior user experience and a robust supply chain. It is essential to build a team and corporate culture that intuitively and strategically understands these concepts and loves working together on meaningful innovation, and I am very excited to join ChroMedX and lead this process."

Mr. Kent has been appointed president and has joined the ChroMedX board of directors. Mr. Kent is a capital markets professional with extensive experience leading corporate development and finance initiatives in the life sciences, technology and natural resource industries. For over a decade, he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.

"As a long-time supporter and consultant, Clark has been instrumental in the advancement of ChroMedX and the HemoPalm technology," said Mr. Edwards. "Clark has most recently been responsible for the company's partnership with DxEconomix and introduction to Lahav Gil. We are very pleased to now welcome him as a director and full-time member of the team as ChroMedX president."

With the appointments of Mr. Gil and Mr. Kent, Ash Kaushal will step down from his president, chief executive officer and director roles. Mr. Kaushal joined the company as president and chief executive officer in July, 2016, after serving as a key consultant since the company's inception. The ChroMedX board of directors would like to thank Mr. Kaushal for his contributions and leadership in 2017. Mr. Kaushal will continue to work with the company on a consulting basis.

With these appointments, ChroMedX has increased its board to six directors. Further information on the company's executive team, board of directors and key advisers can be found on the ChroMedX website.

About Lahav Gil

Mr. Gil is the founder and former chief executive officer of the Toronto-based Kangaroo Group, which he built into a national brand and recently sold to Starfish Medical of Vancouver Island. He is passionate about meaning, loves innovation culture, values-based leadership, transparency and awareness. Mr. Gil has deep experience in medtech product development and business. He has founded/co-founded six companies and has accompanied many Canadian start-ups on their journey from napkin to launch, critically contributing to their investability, clinical and market readiness. He has contributed to over 200 technology product launches and to game-changing innovations for companies such as: Imris, Fio, fSona, Cellaegis, Xor, Ultrasonix, Exact Imaging, Sciex and others.

For almost three decades, he has been involved with technology innovation, entrepreneurship and start-up companies, starting in Israel's bustling innovation climate of the 1980s. During the late 1990s, Mr. Gil integrated into the Canadian innovation scene, leading industrial design projects and corporate-wide iD strategy for Creo/Kodak in Vancouver, where he first got a taste of the crucial role of culture in business. In 2003, he founded Kangaroo Design, which he evolved into the Kangaroo Group (ISO 13485), a full-spectrum outsourcing platform for medical devices innovation, engineering, design, productization, RA submissions and contract manufacturing.

Under his leadership, Kangaroo supplied services, infrastructure, and incubation partnerships to Canadian medtech start-ups and entrepreneurs for over 15 years. During this time, Mr. Gil's main focus was building Kangaroo as a platform alongside spin-ins, spinouts and incubation investments.

Recent news

ChroMedX most recently announced the signing of a definitive agreement with diagnostics marketing experts DxEconomix to lead initiatives relating to potential high-value transactions. Further information can be found on the company's website.

About ChroMedX Corp.

ChroMedX is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

[Popeye82]

Antwort auf Beitrag Nr.: 56.622.824 von Antropophagi am 05.01.18 08:10:08

Sie haben Ein paar sehr schöne Schreiben möchte ich nur Einmal anmerken.

[Hoermen]

BaFin

Nun ja, die BaFin. Liest man sich den Artikel von Bullinger durch, kann man tatsächlich nur den Kopf schütteln. In Kanada jedenfalls kaufen Banken und institutionelle Investoren diese Aktie scheinbar ohne Probleme.
https://www.bullvestorbb.com/kolumne-danke-bafin-oder-wie-ma…

[Coolbleiben]

Antwort auf Beitrag Nr.: 56.622.824 von Antropophagi am 05.01.18 08:10:08

Hallo Antro

Dein Beitrag gefällt mir ausgezeichnet


Wünsche dir ein tolles Wochenende

Coolbleiben

[partisan0815]

wurde für dieses Gerät

nicht schon mitte 2016 durch bullvestor
hier Stimmung gemacht,oder ist das ein anderes?
https://www.irw-press.com/de/news/chromedx-beantragt-globale…

[Antropophagi]

Antwort auf Beitrag Nr.: 56.621.840 von partisan0815 am 05.01.18 00:01:10

Weil kein bigplayer ein Tool kaufen kann/will das kein FDA approval hat.. Mensch Leute benutzt doch ab und an Mal eure Augen zum lesen und den die wabbelige Masse unter euren Haaren zum Denken..

[hp690ccc]

Hallo zusammen,